Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis

05-03-2025 | Thrombosis

Unveiling the complexities of catheter-related thrombosis: risk factors, preventive strategies, and management

Authors: Hannah L. King, Thalia Padilla-Lazos, Akshit Chitkara, Virginia Tan, Genevieve B. Benedetti, Aya Agha, Kylee L. Martens, Joseph J. Shatzel

Published in: Journal of Thrombosis and Thrombolysis

Login to get access

Abstract

Catheter-related deep venous thrombosis (CR-DVT) is a common complication of central venous catheters, however optimal prophylactic and treatment strategies have yet to be fully defined. While the use of anticoagulation for CR-DVT prophylaxis is not routinely recommended, current available data offer heterogeneous results due to small sample size, non-uniform study design, and varying comorbid conditions. Available guidelines for the treatment of CR-DVT generally recommend a limited duration of anticoagulation after catheter removal. If ongoing use is required and the device remains functional, guidelines support anticoagulation throughout the time the catheter remains in place. It is worth acknowledging that data guiding these recommendations is largely derived from observational studies of upper extremity CR-DVT, along with randomized trials of anticoagulation in patients with lower extremity DVT. Therefore, large, randomized controlled trials are desperately needed to define optimal management, especially in patients who are at high risk for bleeding. This review explores the epidemiology and risk factors of CR-DVT, diagnostic, prophylactic and treatment strategies, guideline recommendations, and future advances in the field, including the introduction of novel anticoagulants. With current available evidence, we also conclude with an individualized approach to preventing and managing CR-DVT to assist clinicians who are faced with this common clinical scenario.

Graphical abstract

Literature
1.
Deere M, Singh A, Burns B (2024) Central venous access of the subclavian Vein, in StatPearls. Treasure Island (FL)
2.
Avery J et al (2023) Risks factors and outcomes for isolated catheter-related deep venous thrombosis in patients undergoing allogeneic hematopoietic stem cell transplantation. Thromb Res 229:1–6PubMedPubMedCentralCrossRef
3.
Chopra V et al (2017) The Michigan risk score to predict peripherally inserted central catheter-associated thrombosis. J Thromb Haemost 15(10):1951–1962PubMedCrossRef
4.
Kirkpatrick A et al (2007) Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med 120(10):901e1–90113CrossRef
5.
Verso M et al (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23(18):4057–4062PubMedCrossRef
6.
Chen P et al (2021) The incidence of asymptomatic thrombosis related to peripherally inserted central catheter in adults: A systematic review and meta-analysis People’s. Nurs Open 8(5):2249–2261PubMedPubMedCentralCrossRef
7.
Chen S et al (2021) DVT incidence and risk factors in critically ill patients with COVID-19. J Thromb Thrombolysis 51(1):33–39PubMedCrossRef
8.
Luciani A et al (2001) Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on doppler US. Radiology 220(3):655–660PubMedCrossRef
9.
Winters JP et al (2015) Central venous catheters and upper extremity deep vein thrombosis in medical inpatients: the medical inpatients and thrombosis (MITH) study. J Thromb Haemost 13(12):2155–2160PubMedCrossRef
10.
Li H et al (2022) Risk factors for central venous catheter-associated deep venous thrombosis in pediatric critical care settings identified by fusion model. Thromb J 20(1):18PubMedPubMedCentralCrossRef
11.
Geerts W (2014) Central venous catheter-related thrombosis. Hematol Am Soc Hematol Educ Program 2014(1):306–311CrossRef
12.
Wang P et al (2022) Risk of VTE associated with ports and PICCs in cancer patients: A systematic review and meta-analysis. Thromb Res 213:34–42PubMedCrossRef
13.
Thomsen SL et al (2024) Safety and efficacy of midline vs peripherally inserted central catheters among adults receiving IV therapy: A randomized clinical trial. JAMA Netw Open 7(2):e2355716PubMedPubMedCentralCrossRef
14.
Swaminathan L et al (2022) Safety and outcomes of midline catheters vs peripherally inserted central catheters for patients with Short-term indications: A multicenter study. JAMA Intern Med 182(1):50–58PubMedCrossRef
15.
Balsorano P et al (2020) Peripherally inserted central catheter-related thrombosis rate in modern vascular access era-when insertion technique matters: A systematic review and meta-analysis. J Vasc Access 21(1):45–54PubMedCrossRef
16.
Marin A et al (2021) Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment. BMJ Support Palliat Care 11(4):371–380PubMedPubMedCentralCrossRef
17.
Chopra V et al (2013) Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 382(9889):311–325PubMedCrossRef
18.
Sharp R et al (2015) The catheter to vein ratio and rates of symptomatic venous thromboembolism in patients with a peripherally inserted central catheter (PICC): a prospective cohort study. Int J Nurs Stud 52(3):677–685PubMedCrossRef
19.
Bhargava M et al (2020) Risk factors for peripherally inserted central catheter line-related deep venous thrombosis in critically ill intensive care unit patients. SAGE Open Med 8:2050312120929238PubMedPubMedCentralCrossRef
20.
Singha P et al (2020) Multipronged approach to combat Catheter-Associated infections and thrombosis by combining nitric oxide and a Polyzwitterion: a 7 day in vivo study in a rabbit model. ACS Appl Mater Interfaces 12(8):9070–9079PubMedPubMedCentralCrossRef
21.
Lutsey PL, Zakai NA (2023) Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol 20(4):248–262PubMedCrossRef
22.
Citla Sridhar D, Abou-Ismail MY, Ahuja SP (2020) Central venous catheter-related thrombosis in children and adults. Thromb Res 187:103–112PubMedCrossRef
23.
Dentali F et al (2008) Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 6(1):70–75PubMedCrossRef
24.
Miri M, Goharani R, Sistanizad M (2017) Deep vein thrombosis among intensive care unit patients; an epidemiologic study. Emerg (Tehran) 5(1):e13PubMed
25.
Nm Bhat M et al (2019) Value of routine sonographic screening of internal jugular vein to detect catheter related thrombosis in intensive care unit. Indian J Crit Care Med 23(7):326–328PubMedPubMedCentralCrossRef
26.
Lorente L et al (2005) Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Crit Care 9(6):R631–R635PubMedPubMedCentralCrossRef
27.
van Rooden CJ et al (2005) Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 23(12):2655–2660PubMedCrossRef
28.
Sakai H, Iwata M, Terasawa T (2023) External validation of the Michigan PICC catheter-associated bloodstream infections score (MPC score) for predicting the risk of peripherally inserted central catheter-associated bloodstream infections: A single-center study in Japan. Infect Control Hosp Epidemiol 44(3):480–483PubMedCrossRef
29.
Kang J et al (2022) Validation of Michigan risk score and D-dimer to predict peripherally inserted central catheter-related thrombosis: A study of 206,132 catheter days. J Vasc Access 23(5):764–769PubMedCrossRef
30.
Yuen HLA et al (2022) Development of a risk score to predict peripherally inserted central catheter thrombosis in active cancer. Intern Med J 52(10):1733–1740PubMedCrossRef
31.
Baarslag HJ et al (2002) Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 136(12):865–872PubMedCrossRef
32.
Kraaijpoel N et al (2020) Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis. PLoS ONE 15(2):e0228788PubMedPubMedCentralCrossRef
33.
Grant JD et al (2012) Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thromb Haemost 108(6):1097–1108PubMedCrossRef
34.
Debourdeau P et al (2013) International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 11(1):71–80PubMedCrossRef
35.
Kearon C et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians Evidence-Based clinical practice guidelines. Chest 141(2 Suppl):e419S–e496SPubMedPubMedCentralCrossRef
36.
Kovacs MJ et al (2007) A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The catheter Study). J Thromb Haemost 5(8):1650–1653PubMedCrossRef
37.
Tung-Chen Y et al (2021) Sonographic evolution of the superficial vein thrombosis of the lower extremity. J Ultrasound 24(3):253–259PubMedCrossRef
38.
Di Nisio M, Wichers IM, Middeldorp S (2018) Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2(2):CD004982PubMed
39.
Beyer-Westendorf J et al (2017) Prevention of thromboembolic complications in patients with superficial-vein thrombosis given Rivaroxaban or Fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 4(3):e105–e113PubMedCrossRef
40.
Stevens SM et al (2024) Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012–2021. Chest 166(2):388–404PubMedCrossRef
41.
Wall C, Moore J, Thachil J (2016) Catheter-related thrombosis: A practical approach. J Intensive Care Soc 17(2):160–167PubMedCrossRef
42.
Lavau-Denes S et al (2013) Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose Warfarin, low molecular weight Heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol 72(1):65–73PubMedCrossRef
43.
Lv S et al (2019) The anticoagulants Rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients. Med (Baltim) 98(47):e17894CrossRef
44.
Boraks P et al (1998) Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 101(3):483–486PubMedCrossRef
45.
Kahale LA et al (2018) Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev 6(6):CD006468PubMed
46.
D’Ambrosio L, Aglietta M, Grignani G (2014) Anticoagulation for central venous catheters in patients with cancer. N Engl J Med 371(14):1362–1363PubMedCrossRef
47.
Lopez-Briz E et al (2022) Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults. Cochrane Database Syst Rev 7(7):CD008462PubMed
48.
Delluc A et al (2015) Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. Thromb Res 135(2):298–302PubMedCrossRef
49.
50.
Porfidia A et al (2020) Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. J Thromb Thrombolysis 50(2):355–360PubMedCrossRef
51.
Davies GA et al (2018) A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). Thromb Res 162:88–92PubMedCrossRef
52.
Fan F et al (2017) Rivaroxaban in the treatment of PICC-associated upper extremity venous thrombosis. Clin Ther 39(9):1882–1888PubMedCrossRef
53.
Kovacs MJ et al (2022) A prospective study of Apixaban for central venous catheter associated upper extremity deep vein thrombosis in Cancer patients: catheter 3. Blood 140(Supplement 1):1245–1246CrossRef
54.
Wang TF et al (2024) Management of catheter-related upper extremity deep vein thrombosis in patients with cancer: a systematic review and meta-analysis. J Thromb Haemost 22(3):749–764PubMedCrossRef
55.
Valeriani E et al (2022) Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and meta-analysis. J Thromb Haemost 20(3):661–670PubMedCrossRef
56.
Vasanthamohan L et al (2018) Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 16(7):1288–1295PubMedCrossRef
57.
Farge D et al (2019) 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566–e581PubMedCrossRef
58.
Debourdeau P et al (2008) SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol, 2009. 20(9): pp. 1459–1471
59.
60.
Sousa B et al (2015) Central venous access in oncology: ESMO clinical practice guidelines. Ann Oncol 26(Suppl 5):v152–v168PubMedCrossRef
61.
Houghton DE et al (2021) Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. Blood Adv 5(14):2807–2812PubMedPubMedCentralCrossRef
62.
Samuelson Bannow BT et al (2018) Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 16(6):1246–1249PubMedCrossRef
63.
Streiff MB et al (2021) Cancer-Associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(10):1181–1201PubMed
64.
Key NS et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496–520PubMedCrossRef
65.
Pfeffer MA et al (2024) Factor XI Inhibition for the prevention of Catheter-Associated thrombosis in patients with Cancer undergoing central line placement: A phase 2 clinical trial. Arterioscler Thromb Vasc Biol 44(1):290–299PubMedCrossRef
66.
Poenou G et al (2023) Inhibition of factor XI: A new era in the treatment of venous thromboembolism in Cancer patients?? Int J Mol Sci, 24(19)
67.
Liu K et al (2018) Handgrip exercise reduces peripherally-inserted central catheter-related venous thrombosis in patients with solid cancers: A randomized controlled trial. Int J Nurs Stud 86:99–106PubMedCrossRef
68.
Boersma RS et al (2015) Concentrated citrate locking in order to reduce the long-term complications of central venous catheters: a randomized controlled trial in patients with hematological malignancies. Support Care Cancer 23(1):37–45PubMedCrossRef
69.
Young AM et al (2009) Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373(9663):567–574PubMedCrossRef
70.
Karthaus M et al (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17(2):289–296PubMedCrossRef
71.
Couban S et al (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23(18):4063–4069PubMedCrossRef
72.
Heidari Gorji MA et al (2015) Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesth Pain Med 5(2):e22595PubMedPubMedCentralCrossRef
73.
Babu BM et al (2014) Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. J Evol Med Dent Sci 3(1):46–51CrossRef
74.
Itkin M et al (2014) Peripherally inserted central catheter thrombosis–reverse tapered versus nontapered catheters: a randomized controlled study. J Vasc Interv Radiol 25(1):85–91e1PubMedCrossRef
75.
Goossens GA et al (2013) Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Ann Oncol 24(7):1892–1899PubMedCrossRef
76.
Schallom ME et al (2012) Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomized trial. Crit Care Med 40(6):1820–1826PubMedCrossRef
77.
Maki DG et al (2011) A novel antimicrobial and antithrombotic lock solution for Hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med 39(4):613–620PubMedCrossRef
78.
Hemmelgarn BR et al (2011) Prevention of dialysis catheter malfunction with Recombinant tissue plasminogen activator. N Engl J Med 364(4):303–312PubMedCrossRef
79.
Power A et al (2009) Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis 53(6):1034–1041PubMedCrossRef
80.
81.
Rabe C et al (2002) Keeping central venous lines open: a prospective comparison of Heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Med 28(8):1172–1176PubMedCrossRef
82.
Baumann Kreuziger L et al (2015) A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. J Vasc Surg Venous Lymphat Disord 3(3):243–250e1PubMedCrossRef
83.
Frank DA et al (2000) The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis 10(3):271–275PubMedCrossRef
84.
Schindler J et al (1999) Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue. Clin Appl Thromb Hemost 5(1):25–29PubMedCrossRef
85.
Rodenhuis S et al (1993) Central venous catheter associated thrombosis of major veins: thrombolytic treatment with Recombinant tissue plasminogen activator. Thorax 48(5):558–559PubMedPubMedCentralCrossRef
Metadata
Title
Unveiling the complexities of catheter-related thrombosis: risk factors, preventive strategies, and management
Authors
Hannah L. King
Thalia Padilla-Lazos
Akshit Chitkara
Virginia Tan
Genevieve B. Benedetti
Aya Agha
Kylee L. Martens
Joseph J. Shatzel
Publication date
05-03-2025
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-025-03073-7

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video
Image Credits